3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
pembrolizumab
29
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Trastuzumab
8
Nivolumab
8
Cisplatin
8
Taxes
7
Gemcitabine
7
Bevacizumab
6
Specimen Handling
5
Oxaliplatin
5
Irinotecan
5
Fluorouracil
5
Cetuximab
5
Biopsy
5
spartalizumab
4
Leucovorin
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
durvalumab
3
atezolizumab
3
aldesleukin
3
X-Rays
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Interviews as Topic
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
Technetium-99
×
Gastrointestinal
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled